Company — Merus B.V.
A clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. (NASDAQ: MRUS)
A clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. (NASDAQ: MRUS)